Welcome to our dedicated page for Biote news (Ticker: BTMD), a resource for investors and traders seeking the latest updates and insights on Biote stock.
Biote Corp (BTMD) delivers innovative hormone optimization solutions through its certified practitioner network. This news hub provides investors and healthcare professionals with timely updates on the company's strategic initiatives in personalized medicine and practice-building technologies.
Access authoritative coverage of Biote's latest developments including regulatory milestones, partnership announcements, and certification program expansions. Our curated news collection helps stakeholders track the company's progress in standardizing hormone therapy protocols while supporting medical practices.
Key updates include earnings reports detailing Biote's practice-building platform growth, analysis of new training modules for practitioners, and coverage of clinical advancements in personalized hormone treatments. Bookmark this page for streamlined access to operational updates and market positioning insights.
Biote Corp. (Nasdaq: BTMD) has partnered with IMAC Holdings (Nasdaq: BACK) to introduce Biote's hormone optimization services in IMAC's outpatient clinics. This collaboration aims to enhance patient care by integrating innovative treatments for obesity and chronic pain. Training for IMAC professionals on the Biote Method is set to begin in September. Biote specializes in building medical practices focused on hormone optimization, while IMAC provides regenerative rehabilitation for musculoskeletal and neurological conditions.
Biote Corp. has received approval from The Nasdaq Stock Market to relist its common stock and warrants. Trading will resume under the ticker symbols BTMD for common stock and BTMDW for warrants starting on August 29, 2022. CEO Terry Weber expressed gratitude for Nasdaq's support in confirming the company meets the initial listing criteria. Biote operates within the hormone optimization sector, providing practitioners with the necessary tools to establish and run hormone therapy centers.
Biote Corp, a leader in hormone optimization, has appointed Samar Kamdar as Chief Financial Officer. Kamdar, with extensive financial leadership experience across various industries, will oversee financial operations to enhance revenue growth and profitability. Previously, he held CFO roles at Slync.io and TaxAct and worked with companies like PepsiCo. CEO Terry Weber expressed confidence in Kamdar's ability to drive capital allocation strategies and optimize growth. Biote focuses on enhancing medical practices related to hormone therapy.
Biote (OTC-PINK:BTMD) issued a correction regarding its operating loss and net income for the three and six months ended June 30, 2022. The corrected figures show a larger operating loss and lower net income than previously reported. Specifically, the loss from operations for Q2 2022 increased to $85,603,000 from $76,186,000, and net income decreased to $40,341,000 from $49,710,000. The corrections stemmed from previously omitted transaction-related expenses, primarily linked to a $7.2 million charge related to a business combination with Haymaker Acquisition Corp. III.
Biote reported strong Q2 2022 financial results, with revenue of $41.4 million, a 19% increase year-over-year, and net income of $49.7 million, a 409% year-over-year rise, primarily due to transaction-related items. Adjusted EBITDA grew 21% to $13.1 million. The company maintains its 2022 revenue guidance of $160-166 million and raises adjusted EBITDA guidance to $47-51 million. Biote is expanding its sales force and exploring markets outside its core geography while focusing on clinical research to enhance its offerings.
biote Corp. (Nasdaq: BTMD) will release its Q2 2022 financial results on August 9, 2022, after market close. A conference call is scheduled for 8:30 a.m. ET on August 10, 2022, where CEO Terry Weber will discuss these results and provide a business update. Biote, a leader in hormone optimization, went public on May 27, 2022. The company offers a range of support to certified practitioners, enhancing hormone therapy through education and software solutions.
Biote Corp. (Nasdaq: BTMD) has appointed Dr. Ross W. McQuivey as Chief Medical Officer, effective June 10, 2022. Dr. McQuivey brings over 20 years of experience in medical leadership, having previously served as CMO at Laborie Medical Technologies. His role will focus on driving clinical research and expanding the Biote Method in mainstream medicine. CEO Terry Weber expressed confidence in Dr. McQuivey’s experience, highlighting its alignment with Biote’s strategic growth plans in the hormone optimization sector.
Biote Corp. (Nasdaq: BTMD) announces a presentation by CEO Terry Weber at the Jefferies 2022 Healthcare Conference on June 8, 2022, at 1:30 p.m. ET, in New York City. The event will be webcasted live with a replay available for 90 days. In addition, Weber and Chairman Marc Beer will engage in investor meetings during the conference. Biote focuses on hormone optimization, training practitioners to detect and address hormone-related aging conditions. The company went public on Nasdaq on May 27, 2022.
Biote Corp., a medical practice-building company specializing in hormone optimization, has completed its business combination with Haymaker Acquisition Corp. III. This transaction, approved on May 24, 2022, allows Biote to enhance its growth and solidify its market position, with shares trading under the ticker BTMD starting May 27, 2022. The company aims to transform hormone optimization through a robust support network for practitioners and expects to report strong Q2 results in August.
FAQ
What is the current stock price of Biote (BTMD)?
What is the market cap of Biote (BTMD)?
